<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74030">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108743</url>
  </required_header>
  <id_info>
    <org_study_id>IRB8603</org_study_id>
    <nct_id>NCT02108743</nct_id>
  </id_info>
  <brief_title>Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension</brief_title>
  <official_title>Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Association Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Association Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if dynamic hyperinflation seen in patients with
      idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only a few small studies have evaluated the relationship between iPAH, expiratory flow
      limitation, and exercise dyspnea. While not all patients with iPAH demonstrate airway
      involvement, those who demonstrate dynamic hyperinflation (DH), defined as a variable and
      temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on
      maximal testing. There is a continued need for adjuvant therapy in iPAH, and bronchodilators
      have the potential to ameliorate dyspnea during exercise, which could lead to improved
      quality of life in this disabling condition. This study will investigate the presence of
      airway involvement in this population as measured by dynamic hyperinflation, and if there is
      any improvement in function with the use of inhaled albuterol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork.</measure>
    <time_frame>up to  3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determined by measuring inspiratory capacity every 2 minutes during cardiopulmonary exercise test (CPET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak oxygen consumption with albuterol</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured at the end of CPET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in O2 pulse with albuterol.</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured throughout CPET and compared at matched metabolic isotimes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise time</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total ramped exercise time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg dyspnea score</measure>
    <time_frame>Days 2 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured every 2 minutes throughout CPET</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Idiopathic Pulmonary Arterial Hypertension.</condition>
  <arm_group>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol.</intervention_name>
    <description>2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
    <arm_group_label>Albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or greater.

          -  Idiopathic Pulmonary Arterial Hypertension, or Familial Pulmonary Arterial
             Hypertension.

          -  Forced expiratory flow 75% (FEF75%) of ≤ 65% of predicted.

        Exclusion Criteria:

          -  Clinical instability or change in medication therapy in preceding 3 months.

          -  Allergy or intolerance to inhaled albuterol.

          -  Body mass index &gt; 30

          -  Active tobacco use, or &gt; 10 pack-year smoking history.

          -  Lung disease other than pulmonary hypertension

          -  Forced expiratory volume in 1 second (FEV1) ≤ 80% of predicted.

          -  Pregnancy

          -  Inability to perform pulmonary function testing.

          -  Inability to perform cardiopulmonary exercise testing.

          -  Supplemental oxygen requirement.

          -  Inability to read and understand English.

          -  Historical 6-minute walk distance &lt;150 meters
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Lammi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center in New Orleans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Lammi, MD</last_name>
    <phone>504-568-4634</phone>
    <email>mlammi@lsuhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>LSUHSC Interim Louisiana Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Lammi, MD</last_name>
      <phone>504-568-4634</phone>
      <email>mlammi@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Lammi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brianne Aiello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Johnson, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bennett deBoisblanc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, Wilkens H, Breuer C, Kübler W, Borst MM; German PPH Study Group. Peripheral airway obstruction in primary pulmonary hypertension. Thorax. 2002 Jun;57(6):473-6.</citation>
    <PMID>12037220</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, Barrios R, Seoane M, Sandoval J. Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). Chest. 1983 May;83(5):732-8.</citation>
    <PMID>6839814</PMID>
  </reference>
  <reference>
    <citation>Laveneziana P, Garcia G, Joureau B, Nicolas-Jilwan F, Brahimi T, Laviolette L, Sitbon O, Simonneau G, Humbert M, Similowski T. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J. 2013 Mar;41(3):578-87. doi: 10.1183/09031936.00223611. Epub 2012 Jul 12.</citation>
    <PMID>22790921</PMID>
  </reference>
  <reference>
    <citation>Spiekerkoetter E, Fabel H, Hoeper MM. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J. 2002 Sep;20(3):524-8.</citation>
    <PMID>12358324</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Matthew Lammi</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Section of Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
